Picture loading failed.

Anti-CD19;CD3E therapeutic antibody (Pre-made Blinatumomab biosimilar,Bispecific T-Cell Engager) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.

Order informatioin


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-074-1mg 1mg 3090
GMP-Bios-ab-074-10mg 10mg 21890
GMP-Bios-ab-074-100mg 100mg 148000
GMP-Bios-ab-074-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Anti-CD19;CD3E therapeutic antibody (Pre-made Blinatumomab biosimilar,Bispecific T-Cell Engager)
INN Name Blinatumomab
TargetCD19;CD3E
FormatBispecific T-Cell Engager
DerivationBispecific antibody
Species ReactivityHuman
CH1 Isotypena
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone;None
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2008
Year Recommended2009
CompaniesAmgen;Astellas Pharma;M. D. Anderson Cancer Center;Merck & Co;Micromet Inc;National Cancer Institute (USA);University of California Davis
Conditions ApprovedPrecursor B-cell lymphoblastic leukaemia-lymphoma
Conditions ActiveNon-Hodgkin's lymphoma;Diffuse large B cell lymphoma;Richter's syndrome;Burkitt's lymphoma
Conditions DiscontinuedChronic lymphocytic leukaemia
Development TechBiTE Technology